Sofinnova News
Antoine Papiernik speaks at Growing Together Athens event
"Europe has everything to be a major player in life sciences"
Related Deal lead
Antoine PapiernikSofinnova Partners' Chairman and Managing Partner, Antoine Papiernik, spoke on April 4th at the opening plenary session of Growing Together Athens, an event that gathered 300 entrepreneurs, investors, bankers and representatives from European institutions.
The inaugural event, organized by the Hellenic Development Bank (HDB) and Bpifrance, the Greek and French national investment banks, provided networking opportunities and a forum to discuss how investors and development banks can come together to drive innovation, growth and economic attractiveness in Europe. In addition, eight Greek entrepreneurs seeking to raise more than €35 million presented their pitches to investors and other stakeholders.
Papiernik's message was one of hope and ambition. In this context, he spoke of Sofinnova Partners' long history — the firm got its start in 1972, with 5 million francs (less than $1 million) under management, and today has more than €2.5 billion under management, and a team of 60 people representing 18 nationalities.
"We believe that Europe has everything it needs in order to be a major player in our field of life sciences," Papiernik said, listing technology, talent and capital as the three key ingredients. In France, he pointed out, mindsets and regulations have changed for the better. Until 1999, Papiernik pointed out, it was not legal for a scientist at a French university to have an ownership stake in a start-up.
Looking to the future, Papiernik said Europe needed to look beyond "unicorns." "Europe needs, within the next 10, 20 years, companies that are worth a hundred billion dollars," he said, adding that, "we need to have what it takes, which is hope and ambition."
Watch the video of Antoine Papiernik's speech
Related News
European Life Sciences Coalition launched to strengthen Europe’s life sciences investment ecosystem
Mainstay Medical Announces Exclusive Coverage of ReActiv8® by Blue Cross Blue Shield
HighLife Receives CE Mark Approval for its TMVR Solution
SafeHeal® Announces Successful Launch of SAFE-3CV IDE Study for Colovac® Anastomosis Protection Technology
May Health Announces CE Mark for Innovative Treatment for Women with PCOS-related Infertility